Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
NCT ID: NCT03298204
Last Updated: 2019-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2762 participants
OBSERVATIONAL
2017-06-01
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
NCT02850991
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
NCT02979691
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
NCT02399306
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
NCT01670409
Comparable Study of Different Radiation Dose in Esophageal Carcinoma
NCT01937208
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chemoradiotherapy
No interventions assigned to this group
Chemoradiotherapy following chemotherapy
No interventions assigned to this group
Chemoradiotherapy followed by chemotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age\>18 years
* No distant metastasis other than supraclavicular lymph nodes
* No prior history of thoracic radiation
* Patients must have normal organ and marrow function as defined below: Leukocytes: greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits
Exclusion Criteria
* Pregnant or lactating females
* Contraindication for radiotherapy or chemotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hebei Medical University Fourth Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV
Anyang Tumor Hospital
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Affiliated Hospital of Hebei University
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Beijing Hospital
OTHER_GOV
Tengzhou Central People's Hospital
OTHER_GOV
PLA Army General Hospital
UNKNOWN
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zefen Xiao
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3JECROG R-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.